Comparative Pharmacology
Head-to-head clinical analysis: ERYC 125 versus ERYTHRA DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC 125 versus ERYTHRA DERM.
ERYC 125 vs ERYTHRA-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
None Documented
None Documented
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic